 |
Postmenopausal Systemic Hormone Therapy: Putting Risks Into Perspective CME/CE Author Information and Disclosures Release Date: January 31, 2008; Valid for credit through January 31, 2009 | Physicians - maximum of 0.5 AMA PRA Category 1 Credit(s)™ for physicians;
Nurses - 0.5 nursing contact hours (0.5 contact hours are in the area of pharmacology) | | To participate in this activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details. Contents of This CME/CE Activity- Postmenopausal Systemic Hormone Therapy: Putting Risks Into PerspectiveWulf H. Utian, MD, PhD, DSc(Med); Howard N. Hodis, MD; Rogerio A. Lobo, MD; Charles L. Loprinzi, MD; Susan Wysocki, RNC, NP, FAANPAvailable As: Slides/Video | Slides/Transcript
Legal DisclaimerThe material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
Comments made during this program are individual opinions and not necessarily the view of The North American Menopause Society (NAMS) or the National Association of Nurse Practitioners in Women's Health (NPWH). Copyright © 2008 Medscape. |
|
|
Learning Objectives Upon completion of this activity, participants will be able to: - Identify clinician and patient concerns related to use of postmenopausal systemic hormone therapy (HT).
- Review the general concepts of risk.
- Describe data regarding risks and HT use.
Authors and Disclosures Wulf H. Utian, MD, PhD, DSc(Med)
Disclosure: Dr. Utian reports: Advisor -- Merck; Meeting participant -- Wyeth; Advisory board -- Duramed, Merrion. Howard N. Hodis, MD
Disclosure: Dr. Hodis reports no significant financial relationships.
Rogerio A. Lobo, MD
Disclosure: Dr. Lobo reports: Advisor -- Bayer, Organon, Ortho-McNeil, Solvay, Wyeth. Charles L. Loprinzi, MD
Disclosure: Dr. Loprinzi reports no significant financial relationships. Susan Wysocki, RNC, NP, FAANP
Disclosure: Ms. Wysocki reports: Advisory board -- Berlex, Digene, Duramed, Esprit,
Eli Lilly, Merck, Organon, Ortho Women's Health, Wyeth. Peggy Keen, PhD, RNC
Disclosure: Peggy Keen PhD, RNC, has disclosed no relevant financial relationships. |
 |
|
The North American Menopause Society (NAMS) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
NAMS designates this educational activity for a maximum of 0.50 AMA PRA Category I Credit™. Each individual should only claim credit commensurate with the extent of their participation in the educational activity.
|
 |
|
Approved by the Continuing Education Approval Program of the National Association of Nurse Practitioners in Women's Health.
This Activity has been evaluated and approved by the Continuing Education Approval Program of the National Association of Nurse Practitioners in Women's Health (NPWH) for 0.50 contact hour of continuing education credit, including 0.50 hour of pharmacology content. Each participant should claim only those contact hours that he/she actually spent in the educational activity.
|
|
